Article
CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.
Genomics, proteomics & bioinformatics - 1 Feb 2020
Li Ziyi, Wang Binbin, Gu Shengqing, Jiang Peng, Sahu Avinash, Chen Chen-Hao, Han Tong, Shi Sailing, Wang Xiaoqing, Traugh Nicole, Liu Hailing, Liu Yin, Wu Qiu, Brown Myles, Xiao Tengfei, Boland Genevieve M, Shirley Liu X
Abstract excerpt
BRAF is a serine/threonine kinase that harbors activating mutations in ∼7% of human malignancies and ∼60% of melanomas. Despite initial clinical responses to BRAF inhibitors, patients frequently develop drug resistance. To identify candidate therapeutic targets for BRAF inhibitor resistant melanoma, we conduct CRISPR screens in melanoma cells harboring an activating BRAF mutation that had also acquired resistance...
Topics
- Cell Line, Tumor
- Cell Proliferation
- Clustered Regularly Interspaced Short Palindromic Repeats
- Drug Resistance, Neoplasm
- Humans
- Indoles
- Intercellular Signaling Peptides and Proteins
- Melanoma
- Mutation